The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Cytokine modulation correlates with symptom improvement in patients with MF treated with nuvisertib
In this video, Lindsay Rein, MD, Duke University Medical Center, Durham, NC, discusses an analysis using longitudinal data from the ongoing Phase I/II study (NCT04176198) evaluating nuvisertib monotherapy in patients with myelofibrosis (MF). This analysis investigated cytokine modulation due to nuvisertib treatment and how this correlates with symptom improvements observed in patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The first question is really to talk a little bit about the nuvisertib abstract, which I’m really excited about. So some lovely correlative cytokine or biomarker data. So for this particular abstract, we utilize patient samples as part of the ongoing clinical study of nuvisertib or TP-3654 in patients with previously treated relapsed/refractory myelofibrosis who had been exposed to previous JAK inhibitor therapy...
The first question is really to talk a little bit about the nuvisertib abstract, which I’m really excited about. So some lovely correlative cytokine or biomarker data. So for this particular abstract, we utilize patient samples as part of the ongoing clinical study of nuvisertib or TP-3654 in patients with previously treated relapsed/refractory myelofibrosis who had been exposed to previous JAK inhibitor therapy. So as part of this clinical trial, we are collecting intermittent samples to be able to look at cytokines and how they change longitudinally in these patients with exposure to nuvisertib again over the course of time. And so really exciting data. And I think what makes it really interesting and impactful is the fact that there were so many cytokines evaluated and so many data points collected. And so what I think is really interesting and exciting about this data set is really just the size and the number and the volume of data points that are evaluated.
And so we looked at clinical samples, again, in patients, and we’re able to evaluate how cytokines changed both longitudinally over time, and we can see different cytokines that were consistently increased with exposure to nuvisertib and then another set of cytokines that were consistently decreased with exposure to nuvisertib. And so that was really one interesting way to evaluate the data. The second way that we looked at this was to actually utilize a modified Kaplan-Meier analysis and to see how different cytokines were modulated over time over the course of the study. And again, we looked at this in the sense of seeing impacts on total symptom scores and how those changed in correlation or in relationship to these different cytokines. And then also to break it down further and to look at specific cytokines and how those changed in relation to specific symptoms that patients were experiencing as a part of this study. And so there were some interesting trends that pulled out. That data was presented and we look forward to seeing that data mature as more patients are enrolled into the study and as we collect more data.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Incyte: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Sobi: Consultancy; DAVA Oncology: Other: Speaker, conference participant; Karyopharm: Other: Site Principal Investigator for clinical trial, Research Funding; PharmaEssentia: Other: Site Principal Investigator for clinical trial, Research Funding; Merck: Other: Site Principal Investigator for clinical trial, Research Funding; Morphpsys: Consultancy; Geron: Other: Site Principal Investigator for clinical trial, Research Funding; Blueprints Medicine: Other: Site Principal Investigator for clinical trial, Research Funding; Protagonist: Other: Site Principal Investigator for clinical trial, Research Funding; Cogent Biosciences: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Sumitomo Dainippon Pharma Oncology: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Novartis: Consultancy, Honoraria, Other: Site Principal Investigator for clinical trial, Research Funding; Abbvie: Consultancy; Telios Pharma: Research Funding; Silence Therapeutics: Research Funding.
